Kairos Pharma, LTD. (KAPA): Entry into a Material Definitive Agreement
Kairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 NOTE: Certain identified information has been excluded from this exhibit and replaced with [***] because it is both (i) not material and (ii) the type of information the Company treats as private or confidential. Agreement for the Support
How this was made
The 30-second read
Why it matters
The agreement sets sponsor responsibilities to initiate, manage, and finance the study, receive study drug from Bayer for the study purpose, and deliver study reports/manuscripts after completion. It also grants Bayer broad, royalty-free rights to access, transfer, and use study results, with long confidentiality and publication review provisions.
Market read
This is a primary disclosure of a new R&D collaboration framework, but the excerpt does not include trial outcomes, economics, or milestone-driven guidance.
What to watch
Confidentiality and IP clauses (royalty-free rights to Bayer for study results) could be viewed as limiting Kairos’ future monetization, offsetting any perceived R&D benefit.
Background
The 8-K Item 1.01 attaches an exhibit describing an Agreement for the Support of Investigator/Institution Initiated Research between Bayer and Kairos as sponsor.
Ticker impact
Kairos Pharma entered a material definitive agreement (8-K Item 1.01) for Bayer-initiated investigator/institution initiated research support.
Likely limited near-term impact unless the study scope or economics are material; could modestly support sentiment around ongoing R&D collaboration.
An 8-K contract disclosure is primary and time-sensitive, but the excerpt provides no financial terms, study size, endpoints, or timeline beyond administrative obligations, limiting expected magnitude.
Market effects
Adds incremental evidence of continued pharma-sponsored investigator research activity, but without disclosed clinical or commercial milestones.
No clear regional read-through from the agreement terms provided.
Bayer involvement suggests cross-border pharma collaboration, but no global regulatory or market access implications are specified.
Counterpoint
Because the excerpt lacks study scope, patient numbers, and any economics, the market may treat this as routine contract boilerplate rather than a value driver.
Key entities
- issuerKairos Pharma, Ltd.
Subject of the 8-K, acting as sponsor under the Bayer IIR support agreement.
- counterpartyBayer HealthCare Pharmaceuticals Inc.
Provides study drug and receives broad rights to study results under the agreement.
